Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer
Data from the phase 1/2 RAINFOL-01 trial support the agency’s regulatory decision on rinatabart sesutecan in advanced endometrial cancer.
Previous Post
Long term safety and efficacy of rabies monoclonal antibody in post-exposure prophylaxis
Next Post
Microneedling with tranexamic acid may improve outcomes for patients with melasma
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago